BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 37306554)

  • 21. Neuropeptide bombesin receptor activation stimulates growth of lung cancer cells through HER3 with a MAPK-dependent mechanism.
    Lee L; Ramos-Alvarez I; Moody TW; Mantey SA; Jensen RT
    Biochim Biophys Acta Mol Cell Res; 2020 Apr; 1867(4):118625. PubMed ID: 31862538
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Perhexiline promotes HER3 ablation through receptor internalization and inhibits tumor growth.
    Ren XR; Wang J; Osada T; Mook RA; Morse MA; Barak LS; Lyerly HK; Chen W
    Breast Cancer Res; 2015 Feb; 17(1):20. PubMed ID: 25849870
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer.
    Lyu H; Wang S; Huang J; Wang B; He Z; Liu B
    Cancer Lett; 2018 Apr; 420():97-108. PubMed ID: 29409974
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of PD-1/L1 inhibitors in brain metastases of non-small-cell lung cancer: pooled analysis from seven randomized controlled trials.
    Li W; Jiang J; Huang L; Long F
    Future Oncol; 2022 Jan; 18(3):403-412. PubMed ID: 34787500
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Checkpoint inhibitors: 'raising the bar' also in brain metastases from non-small-cell lung cancer?
    Rossi S; Finocchiaro G; Marchetti S; Toschi L; Santoro A
    Immunotherapy; 2018 Apr; 10(5):403-410. PubMed ID: 29473467
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world disease burden and outcomes of brain metastases in
    Nadler E; Espirito JL; Pavilack M; Baidoo B; Fernandes A
    Future Oncol; 2020 Aug; 16(22):1575-1584. PubMed ID: 32495656
    [No Abstract]   [Full Text] [Related]  

  • 27. Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines.
    Momeny M; Saunus JM; Marturana F; McCart Reed AE; Black D; Sala G; Iacobelli S; Holland JD; Yu D; Da Silva L; Simpson PT; Khanna KK; Chenevix-Trench G; Lakhani SR
    Oncotarget; 2015 Feb; 6(6):3932-46. PubMed ID: 25668816
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of afatinib, an irreversible ErbB family blocker, in the treatment of intracerebral metastases of non-small cell lung cancer in mice.
    Zhang SR; Zhu LC; Jiang YP; Zhang J; Xu RJ; Xu YS; Xia B; Ma SL
    Acta Pharmacol Sin; 2017 Feb; 38(2):233-240. PubMed ID: 27840411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EGF receptor activates MET through MAPK to enhance non-small cell lung carcinoma invasion and brain metastasis.
    Breindel JL; Haskins JW; Cowell EP; Zhao M; Nguyen DX; Stern DF
    Cancer Res; 2013 Aug; 73(16):5053-65. PubMed ID: 23794705
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world utilization of EGFR TKIs and prognostic factors for survival in EGFR-mutated non-small cell lung cancer patients with brain metastases.
    Yu X; Sheng J; Pan G; Fan Y
    Int J Cancer; 2021 Sep; 149(5):1121-1128. PubMed ID: 33970485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody-Drug Conjugate HER3-DXd.
    Haikala HM; Lopez T; Köhler J; Eser PO; Xu M; Zeng Q; Teceno TJ; Ngo K; Zhao Y; Ivanova EV; Bertram AA; Leeper BA; Chambers ES; Adeni AE; Taus LJ; Kuraguchi M; Kirschmeier PT; Yu C; Shiose Y; Kamai Y; Qiu Y; Paweletz CP; Gokhale PC; Jänne PA
    Cancer Res; 2022 Jan; 82(1):130-141. PubMed ID: 34548332
    [TBL] [Abstract][Full Text] [Related]  

  • 32. hMENA(11a) contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells.
    Trono P; Di Modugno F; Circo R; Spada S; Di Benedetto A; Melchionna R; Palermo B; Matteoni S; Soddu S; Mottolese M; De Maria R; Nisticò P
    Oncogene; 2016 Feb; 35(7):887-96. PubMed ID: 25961924
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting HER proteins in cancer therapy and the role of the non-target HER3.
    Hsieh AC; Moasser MM
    Br J Cancer; 2007 Aug; 97(4):453-7. PubMed ID: 17667926
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management and Outcomes of Newly Diagnosed Non-Small Cell Lung Cancer Patients with Brain Metastases: A Real-World Study in Japan.
    Yoshida H; Kim YH; Iwatsubo S; Sakaguchi C; Sakamori Y; Nagai H; Ozasa H; Mio T; Hirai T
    Oncology; 2020; 98(7):460-467. PubMed ID: 32222702
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systemic treatments for brain metastases from breast cancer, non-small cell lung cancer, melanoma and renal cell carcinoma: an overview of the literature.
    Lombardi G; Di Stefano AL; Farina P; Zagonel V; Tabouret E
    Cancer Treat Rev; 2014 Sep; 40(8):951-9. PubMed ID: 24909312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant,
    Jänne PA; Baik C; Su WC; Johnson ML; Hayashi H; Nishio M; Kim DW; Koczywas M; Gold KA; Steuer CE; Murakami H; Yang JC; Kim SW; Vigliotti M; Shi R; Qi Z; Qiu Y; Zhao L; Sternberg D; Yu C; Yu HA
    Cancer Discov; 2022 Jan; 12(1):74-89. PubMed ID: 34548309
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination.
    Balz LM; Bartkowiak K; Andreas A; Pantel K; Niggemann B; Zänker KS; Brandt BH; Dittmar T
    J Pathol; 2012 Jun; 227(2):234-44. PubMed ID: 22262199
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Down-regulated microRNA-375 expression as a predictive biomarker in non-small cell lung cancer brain metastasis and its prognostic significance.
    Chen LJ; Li XY; Zhao YQ; Liu WJ; Wu HJ; Liu J; Mu XQ; Wu HB
    Pathol Res Pract; 2017 Aug; 213(8):882-888. PubMed ID: 28688608
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The prospect of patritumab for treating non-small cell lung cancer.
    Horinouchi H
    Expert Opin Biol Ther; 2016 Dec; 16(12):1549-1555. PubMed ID: 27744717
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity.
    Lindberg K; Helguero LA; Omoto Y; Gustafsson JÅ; Haldosén LA
    Breast Cancer Res; 2011 Apr; 13(2):R43. PubMed ID: 21492444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.